153 related articles for article (PubMed ID: 35129428)
1.
Zhao J; Pan B; Zhou X; Wu C; Hao F; Zhang J; Liu L
Bioengineered; 2022 Feb; 13(2):2992-3006. PubMed ID: 35129428
[TBL] [Abstract][Full Text] [Related]
2. Luteolin Isolated from
Xiong Y; Zhong W; Liu J; Cheng B; Fan J; Zhou F; He L; Tian D; He Y
Biomed Res Int; 2022; 2022():9740066. PubMed ID: 36588531
[TBL] [Abstract][Full Text] [Related]
3. Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Sieb.et Zucc.: a review.
Peng W; Qin R; Li X; Zhou H
J Ethnopharmacol; 2013 Jul; 148(3):729-45. PubMed ID: 23707210
[TBL] [Abstract][Full Text] [Related]
4. Advances for pharmacological activities of
Ke J; Li MT; Xu S; Ma J; Liu MY; Han Y
Pharm Biol; 2023 Dec; 61(1):177-188. PubMed ID: 36620922
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.
Xi Y; Qi Z; Ma J; Chen Y
Clin Exp Metastasis; 2020 Feb; 37(1):173-185. PubMed ID: 31571016
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the action mechanism of
Pan B; Shi X; Ding T; Liu L
Am J Transl Res; 2019; 11(11):6790-6811. PubMed ID: 31814888
[TBL] [Abstract][Full Text] [Related]
7. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
8. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Tchaicha J; Kikuchi E; Wong KK; Kufe D
Clin Cancer Res; 2014 Nov; 20(21):5423-34. PubMed ID: 25189483
[TBL] [Abstract][Full Text] [Related]
9.
Tao T; Zhang Q; Liu Z; Zhang T; Wang L; Liu J; He T; Chen Y; Feng J; Chen Y
Oxid Med Cell Longev; 2021; 2021():3830671. PubMed ID: 34925692
[No Abstract] [Full Text] [Related]
10. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
11. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma.
Do SI; Jung WW; Kim HS; Park YK
Int J Oncol; 2009 Mar; 34(3):797-803. PubMed ID: 19212684
[TBL] [Abstract][Full Text] [Related]
12. CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.
Wan Z; Huang S; Mo F; Yao Y; Liu G; Han Z; Chen M; Zhiyun L
Exp Cell Res; 2019 Nov; 384(2):111646. PubMed ID: 31560888
[TBL] [Abstract][Full Text] [Related]
13. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
14. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
15. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
16. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).
Mukohara T; Kudoh S; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Wanibuchi H; Fukushima S; Inoue K; Yoshikawa J
Lung Cancer; 2003 Aug; 41(2):123-30. PubMed ID: 12871775
[TBL] [Abstract][Full Text] [Related]
17. Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway.
Liu M; Zhang J; Dong H; Wang W
J Cell Physiol; 2019 Nov; 234(11):20879-20887. PubMed ID: 31001861
[TBL] [Abstract][Full Text] [Related]
18. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
19. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
20. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
Puglisi M; Thavasu P; Stewart A; de Bono JS; O'Brien ME; Popat S; Bhosle J; Banerji U
Lung Cancer; 2014 Aug; 85(2):141-6. PubMed ID: 24957682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
